Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo
Max Medina-Ramírez,Fernando Garces,Amelia Escolano,Patrick Skog,Steven W. de Taeye,Ivan Del Moral-Sanchez,Andrew T. McGuire,Anila Yasmeen,Anna-Janina Behrens,Gabriel Ozorowski,Tom L.G.M. van den Kerkhof,Natalia T. Freund,Pia Dosenovic,Yuanzi Hua,Alexander D. Gitlin,Albert Cupo,Patricia van der Woude,Michael Golabek,Kwinten Sliepen,Tanya Blane,Neeltje Kootstra,Mariëlle J. van Breemen,Laura K. Pritchard,Robyn L. Stanfield,Max Crispin,Andrew B. Ward,Leonidas Stamatatos,Per Johan Klasse,John P. Moore,David Nemazee,Michel C. Nussenzweig,Ian A. Wilson,Rogier W. Sanders
DOI: https://doi.org/10.1084/jem.20161160
2017-08-28
Abstract:Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advance toward an effective vaccine. A critical step in this process is the activation of naive B cells expressing germline (gl) antibody precursors that have the potential to evolve into bNAbs. Here, we reengineered the BG505 SOSIP.664 glycoprotein to engage gl precursors of bNAbs that target either the trimer apex or the CD4-binding site. The resulting BG505 SOSIP.v4.1-GT1 trimer binds multiple bNAb gl precursors in vitro. Immunization experiments in knock-in mice expressing gl-VRC01 or gl-PGT121 show that this trimer activates B cells in vivo, resulting in the secretion of specific antibodies into the sera. A crystal structure of the gl-targeting trimer at 3.2-Å resolution in complex with neutralizing antibodies 35O22 and 9H+109L reveals a native-like conformation and the successful incorporation of design features associated with binding of multiple gl-bNAb precursors.
immunology,medicine, research & experimental